You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Cranial Neurosurgery Simulator and Assessment of Minimally Invasive Techniques
SBC: Simulated Inanimate Models LLC Topic: 103Project SummarySimulation training is unique in its ability for repetitive practice of a wide variety of scenarios and to reflect on performance without jeopardizing a patient s safetySurgical skills simulators have been successful in bridging gaps of the current training modelhoweverthese simulators fall short of offering a complete operative experienceOperative exposure with live patients still ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based
SBC: KLEIN BUENDEL, INC Topic: 102Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel Home-Based and Low-Cost ECG Device for periodic evaluation of the presence of atrial fibrillation
SBC: Global Instrumentation, LLC Topic: 600Abstract Atrial fibrillation (AF) prevalence is estimated to 1% of the general population in the United States. A shocking 30% to 60% (according to studies) of patients with AF are unaware of their diagnosis (silent AF). Most AF patients will suffer from congestive heart failure or/and develop thromboembolic events leading to a dramatic reduction of patients’ quality of life, and a significant c ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LystaMab Immunotherapy to Inhibit Pericardial Adhesions
SBC: LYST THERAPEUTICS LLC Topic: NHLBISUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Protect the Lung from Oxidant Stress
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management
SBC: VASCULAR VISION PHARMACEUTICAL CO Topic: NHLBIAbstractThe pathogenesis of Sickle cell diseaseSCDcomprises a complex interplay of factors associated with vascular endothelial activationintense inflammationand increased sickle cell adhesionMicrovascular occlusion in SCD is initiated by adhesion of sickle red blood cellsRBCsto the endotheliumleading to acute painful vasoocclusive crisisVOCand the clinical morbidity in SCDTreatment strategies inc ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH
SBC: Data2Care Technologies, LLC Topic: NICHDProject Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.
SBC: Oncoimmune Inc Topic: 100Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Optimizing membrane repair for the treatment of Duchenne muscular dystrophy
SBC: Myos, Inc. Topic: NIAMSPROJECT ABSTRACT The long term goal of this project is to optimize a protein therapeutic for Duchenne muscular dystrophyDMDand potentially other muscle diseasesthat will enhance the repair capacity of muscle cell membranes that are compromised by mutations in the dystrophin dystroglycan complexMutations in the dystrophin dystroglycan complex result in Duchenne muscular dystrophyMyos Incis developi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health